ABSTRACT
BACKGROUND AIMS: Current treatment target toward advanced colorectal cancers is mainly focused on the epidermal growth factor receptor (EGFR) signaling, but its additive effects with chemotherapy are still limited. A disintegrin and metalloproteinase (ADAM) cleaves the proheparin-binding epidermal growth factor like growth factor (proHB-EGF). And soluble HB-EGF activates EGFR. In parallel, the carboxy-terminal fragment of proHB-EGF (HB-EGF-CTF) translocates into the inner nuclear membrane, and subsequently exerts on the regulation of cell proliferation by binding nuclear promyelocytic leukemia zinc finger (PLZF) protein, a transcriptional repressor, thereby causing its nuclear export. We hypothesized that the inhibition of HB-EGF-CTF nuclear translocation may be a new strategy in preventing cell proliferation. METHODS: 12-O-tetradecanoylphorbor-13-acetate (TPA) was treated to activate ADAM. Nine-thousand chemical compounds were screened for their efficacies in blocking the binding of HB-EGF-CTF to promyelocytic leukemia zinc finger (PLZF) with Alphascreen system. The obtained candidates were then used to block the binding of HB-EGF-CTF to PLZF in colon cancer cells, HT29 and HCT116. Cell proliferation was investigated with a growth curve assay. The intracellular localization, and association between HB-EGF-CTF and PLZF, was assessed with immunofluorescent staining, and immunoprecipitation and Western blotting, respectively. The effects of obtained candidates on EGFR phosphorylation and on nuclear translocation of HB-EGF-CTF and export of PLZF during the angiotensin II type1 receptor (AT1R) knockdown were also investigated. RESULTS: Telmisartan and candesartan were found to be potential candidates. Telmisartan inhibited TPA-induced cell proliferation stronger than candesartan. Telmisartan, but not candesartan blocked the nuclear translocation of HB-EGF-CTF, and binding of HB-EGF-CTF to PLZF, during TPA stimulation. Both telmisartan and candesartan did not inhibit TPA-induced EGFR phosphorylation, and telmisartan, but not candesartan, inhibited TPA-induced nuclear translocation of HB-EGF-CTF after knockdown of AT1R. CONCLUSIONS: The inhibition of HB-EGF-CTF nuclear translocation with telmisartan may be a novel strategy in preventing cell proliferation.
Subject(s)
Benzimidazoles/pharmacology , Benzoates/pharmacology , Cell Nucleus/metabolism , Colonic Neoplasms/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Cell Line, Tumor , Cell Nucleus/drug effects , Cell Proliferation/drug effects , Heparin-binding EGF-like Growth Factor , Humans , Phorbol Esters/pharmacology , Protein Transport/drug effects , TelmisartanABSTRACT
The specificities of nine approved tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, and pazopanib) were determined by activity-based kinase profiling using a large panel of human recombinant active kinases. This panel consisted of 79 tyrosine kinases, 199 serine/threonine kinases, three lipid kinases, and 29 disease-relevant mutant kinases. Many potential targets of each inhibitor were identified by kinase profiling at the K(m) for ATP. In addition, profiling at a physiological ATP concentration (1 mm) was carried out, and the IC(50) values of the inhibitors against each kinase were compared with the estimated plasma-free concentration (calculated from published pharmacokinetic parameters of plasma C(trough) and C(max) values). This analysis revealed that the approved kinase inhibitors were well optimized for their target kinases. This profiling also implicates activity at particular off-target kinases in drug side effects. Thus, large-scale kinase profiling at both K(m) and physiological ATP concentrations could be useful in characterizing the targets and off-targets of kinase inhibitors.
Subject(s)
Protein Kinase Inhibitors/pharmacology , Protein Kinases/metabolism , Proteome , Adenosine Triphosphate/metabolism , Enzyme Activation/drug effects , Gene Expression Profiling , Humans , Inhibitory Concentration 50 , Kinetics , Mutation , Phylogeny , Protein Binding , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinases/classification , Protein Kinases/genetics , Reproducibility of ResultsABSTRACT
Angiogenic homeostasis is maintained by a balance between vascular endothelial growth factor (VEGF) and Notch signaling in endothelial cells (ECs). We screened for molecules that might mediate the coupling of VEGF signal transduction with down-regulation of Notch signaling, and identified B-cell chronic lymphocytic leukemia/lymphoma6-associated zinc finger protein (BAZF). BAZF was induced by VEGF-A in ECs to bind to the Notch signaling factor C-promoter binding factor 1 (CBF1), and to promote the degradation of CBF1 through polyubiquitination in a CBF1-cullin3 (CUL3) E3 ligase complex. BAZF disruption in vivo decreased endothelial tip cell number and filopodia protrusion, and markedly abrogated vascular plexus formation in the mouse retina, overlapping the retinal phenotype seen in response to Notch activation. Further, impaired angiogenesis and capillary remodeling were observed in skin-wounded BAZF(-/-) mice. We therefore propose that BAZF supports angiogenic sprouting via BAZF-CUL3-based polyubiquitination-dependent degradation of CBF1 to down-regulate Notch signaling.
Subject(s)
Cullin Proteins/metabolism , Neovascularization, Physiologic , Receptors, Notch/metabolism , Repressor Proteins/metabolism , Repressor Proteins/physiology , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Animals , Biomarkers/metabolism , Blotting, Western , Cell Communication , Cells, Cultured , Chromatin Immunoprecipitation , Cullin Proteins/antagonists & inhibitors , Cullin Proteins/genetics , Gene Expression Profiling , Human Umbilical Vein Endothelial Cells/metabolism , Immunoglobulin J Recombination Signal Sequence-Binding Protein/antagonists & inhibitors , Immunoglobulin J Recombination Signal Sequence-Binding Protein/genetics , Immunoglobulin J Recombination Signal Sequence-Binding Protein/metabolism , Immunoprecipitation , Luciferases/metabolism , Mice , Mice, Knockout , Morphogenesis , Oligonucleotide Array Sequence Analysis , Polyubiquitin/metabolism , Pseudopodia/metabolism , RNA, Messenger/genetics , RNA, Small Interfering/genetics , Real-Time Polymerase Chain Reaction , Receptors, Notch/antagonists & inhibitors , Receptors, Notch/genetics , Repressor Proteins/antagonists & inhibitors , Repressor Proteins/genetics , Retina/cytology , Retina/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Skin/injuries , Skin/metabolism , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-1/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-1/genetics , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2/genetics , Wound HealingABSTRACT
A disintegrin and metalloprotease 12 (ADAM12/meltrin alpha) is a key enzyme implicated in the ectodomain shedding of membrane-anchored heparin-binding epidermal growth factor (EGF)-like growth factor (proHB-EGF)-dependent epidermal growth factor receptor (EGFR) transactivation. However, the activation mechanisms of ADAM12 are obscure. To determine how ADAM12 is activated, we screened proteins that bind to the cytoplasmic domain of ADAM12 using a yeast two-hybrid system and identified a protein called PACSIN3 that contains a Src homology 3 domain. An analysis of interactions between ADAM12 and PACSIN3 using glutathione S-transferase fusion protein revealed that a proline-rich region (amino acid residues 829-840) of ADAM12 was required to bind PACSIN3. Furthermore, co-immunoprecipitation and co-localization analyses of ADAM12 and PACSIN3 proteins also revealed their interaction in mammalian cells expressing both of them. The overexpression of PACSIN3 in HT1080 cells enhanced 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced proHB-EGF shedding. Furthermore, knockdown of endogenous PACSIN3 by small interfering RNA in HT1080 cells significantly attenuated the shedding of proHB-EGF induced by TPA and angiotensin II. Our data indicate that PACSIN3 has a novel function as an up-regulator in the signaling of proHB-EGF shedding induced by TPA and angiotensin II.
Subject(s)
Epidermal Growth Factor/chemistry , Membrane Proteins/chemistry , Metalloendopeptidases/chemistry , Muscle Proteins/chemistry , Phosphoproteins/physiology , ADAM Proteins , ADAM12 Protein , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Angiotensin II/chemistry , Cell Line , Cell Membrane/metabolism , Cytoplasm/metabolism , Cytoskeletal Proteins , Epidermal Growth Factor/metabolism , Gene Deletion , Genetic Vectors , Glutathione Transferase/metabolism , Heparin-binding EGF-like Growth Factor , Humans , Immunoblotting , Intercellular Signaling Peptides and Proteins , Intracellular Signaling Peptides and Proteins , Membrane Proteins/metabolism , Metalloendopeptidases/metabolism , Microscopy, Confocal , Molecular Sequence Data , Muscle Proteins/metabolism , Phosphoproteins/metabolism , Precipitin Tests , Proline/chemistry , Protein Binding , Protein Structure, Tertiary , RNA, Small Interfering/metabolism , Recombinant Fusion Proteins/metabolism , Tetradecanoylphorbol Acetate , Transcriptional Activation , Transfection , Two-Hybrid System Techniques , Up-RegulationABSTRACT
Interleukin 18 induces both T helper 1 and T helper 2 cytokines, proinflammatory cytokines, chemokines, and IgE and IgG1 production. A role of interleukin 18 in inflammatory cutaneous reactions is still unclear, however. Here we generated keratin 5/interleukin 18 transgenic mice overexpressing mature murine interleukin 18 in the skin using a human keratin 5 promoter. In the contact hypersensitivity model, trinitrochlorobenzene elicited a stronger ear swelling in keratin 5/interleukin 18 transgenic mice compared with control littermate wild-type or immunoglobulin/interleukin 18 transgenic mice in which mature interleukin 18 was expressed by B and T cells under the control of the immunoglobulin promoter. Application of an irritant, croton oil, induced stronger and more sustained ear swelling in keratin 5/interleukin 18 transgenic mice than in immunoglobulin/interleukin 18 transgenic or wild-type mice. Repetitive topical application (weekly for six consecutive weeks) of trinitrochlorobenzene to their ears also elicited a stronger cutaneous inflammation in keratin 5/interleukin 18 transgenic mice than seen in immunoglobulin/interleukin 18 transgenic or wild-type mice. After these six trinitrochlorobenzene applications, the expression of interferon-gamma, interleukin-4, and CCL20 mRNA in the ear tissue was increased and dermal changes, such as acanthosis and eosinophilic, neutrophilic, and mast cell infiltration, were greater in keratin 5/interleukin 18 transgenic mice than in wild-type mice. Furthermore, the repetitive application elicited a significant increase in serum IgE levels and the number of B cells in the draining lymph node in keratin 5/interleukin 18 transgenic mice. These results suggest that overexpression of interleukin 18 in the skin aggravates allergic and nonallergic cutaneous inflammation, which is accompanied by high expression of T helper 1 and T helper 2 cytokines and chemokines in the skin.
Subject(s)
Dermatitis, Allergic Contact/immunology , Dermatitis, Allergic Contact/physiopathology , Interleukin-18/genetics , Interleukin-18/immunology , Skin/immunology , Animals , Cell Lineage/immunology , Chemokines/genetics , Croton Oil , Cytokines/genetics , Dermatitis, Allergic Contact/pathology , Ear, External , Female , Gene Expression/immunology , Irritants , Keratin-15 , Keratin-5 , Keratinocytes/pathology , Keratinocytes/physiology , Keratins/genetics , Lymph Nodes/cytology , Lymph Nodes/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Picryl Chloride , Promoter Regions, Genetic , RNA, Messenger/analysis , Skin/pathologyABSTRACT
The in vivo effects of IL-18 on bone metabolism were investigated by histopathology in IL-18 transgenic mice. Deformed cortical bone and decreased turnover rate of lumbar trabecular bone are consistent with increased expression of IFN-gamma and IL-18 in the bone marrow. Interleukin (IL)-18 has been demonstrated to inhibit osteoclastogenesis in an in vitro co-culture system. We investigated the effects of IL-18 overexpression on bone metabolism by comparing bone characteristics in male IL-18 transgenic (TG) mice, which secrete mature murine IL-18 from their B- and T-cells, and their wildtype littermates (WT). Histopathological analysis revealed that the cortical bone of the femur was thinner and more deformed in IL-18 TG mice. Bone histomorphometry showed that the cortical bone area of the mid-diaphysis of the femur and the trabecular bone volume of the lumbar vertebrae were significantly reduced in IL-18 TG mice. IL-18 TG mice also exhibited significantly fewer osteoclasts and a reduced bone formation rate in the trabecular bones of their lumbar vertebrae. Real-time reverse transcriptase-polymerase chain reaction amplification of bone marrow cell mRNA revealed that interferon (IFN)-gamma mRNA expression was significantly increased, whereas IL-4 mRNA expression was significantly reduced, in IL-18 TG mice. However, the expression ratio of receptor activator of NFkappaB ligand and osteoprotegerin mRNA was not significantly altered. Thus, deformed cortical bone and a decreased turnover rate of lumbar trabecular bone are characteristic of IL-18 TG mice, and these features might be associated with the increased expression of IFN-gamma and IL-18 in the bone marrow.
Subject(s)
Bone and Bones/abnormalities , Interleukin-18/physiology , Animals , B-Lymphocytes/immunology , Base Sequence , Bone Density , Crosses, Genetic , DNA Primers , Femur/pathology , Glycoproteins/genetics , Humans , Interferon-gamma/genetics , Interleukin-18/genetics , Interleukin-18/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Osteoclasts/cytology , Osteoclasts/drug effects , Osteoprotegerin , RNA, Messenger/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Tumor Necrosis Factor , Reference Values , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/immunology , Transcription, GeneticABSTRACT
A series of phosphonamide-based hydroxamate derivatives were synthesized, and the inhibitory activities were evaluated against various metalloproteinases in order to clarify its selectivity profile. Among the four diastereomeric isomers resulting from the chirality at the C-3 and P atoms, the compound with a (R,R)-configuration both at the C-3 position and the phosphorus atom was found to be potently active, while the other diastereomeric isomers were almost inactive. A number of (R,R)-compounds synthesized here exhibited broad spectrum activities with nanomolar K(i) values against MMP-1, -3, -9, and TACE and also showed nanomolar IC(50) values against HB-EGF shedding in a cell-based inhibition assay. The modeling study using X-ray structure of MMP-3 suggested the possible binding mode of the phosphonamide-based inhibitors.
Subject(s)
Amides/chemical synthesis , Hydroxamic Acids/chemical synthesis , Metalloendopeptidases/antagonists & inhibitors , Organophosphonates/chemical synthesis , Protease Inhibitors/chemical synthesis , Amides/chemistry , Amides/pharmacology , Crystallography, X-Ray , Epidermal Growth Factor/antagonists & inhibitors , Heparin-binding EGF-like Growth Factor , Humans , Hydroxamic Acids/chemistry , Hydroxamic Acids/pharmacology , Intercellular Signaling Peptides and Proteins , Matrix Metalloproteinase 1/chemistry , Matrix Metalloproteinase 3/chemistry , Matrix Metalloproteinase 9/chemistry , Matrix Metalloproteinase Inhibitors , Metalloendopeptidases/chemistry , Models, Molecular , Organophosphonates/chemistry , Organophosphonates/pharmacology , Protease Inhibitors/chemistry , Protease Inhibitors/pharmacology , Protein Binding , Recombinant Proteins/chemistry , Stereoisomerism , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
The ADAM family of membrane-anchored proteins has a unique domain structure, with each containing a disintegrin and metalloprotease (ADAM) domain. We have isolated mouse and human cDNAs encoding a novel member of the ADAM family. The mouse and human predicted proteins consisted of 797 and 813 amino acids, respectively, and they shared 70% homology of the entire amino acid sequence. The mouse ADAM gene exists at a single gene locus. The human gene was ubiquitously expressed in tissues other than liver, was mapped to human chromosome 20p13, and was found to consist of 22 exons. Both proteins have domain organization identical to that of previously reported members of the ADAM family, and contain the typical zinc-binding consensus sequence (HEXGHXXGXXHD) in their metalloprotease domain and a pattern of cysteine localization (C(x)(3)C(x)(5)C(x)(5)CxC(x)(8)C) in their EGF-like domain that is typical of an EGF-like motif. The human protein shows homology with Xenopus ADAM13 (44%), human ADAM19 (40%), and human ADAM12 (39%). From the results of phylogenic analysis based on primary amino acid sequence and distribution of the mRNA, these novel ADAM genes were thus named ADAM33.
